Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henlius Finds Global Partner For Ophthalmic Bevacizumab

Strikes Deal With Essex Bio-Technology For Biosimilar Avastin Rival

Executive Summary

Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.

You may also be interested in...



Eurofarma Biosimilars Deal Broadens Access To Latin America For Henlius

Shanghai Henlius Biotech has announced a licensing deal for three biosimilars – bevacizumab, rituximab and trastuzumab – with Brazil’s Eurofarma. The agreement, which could be worth as much as $50.5m, gives the Chinese company enhanced access to Latin America as it continues to broaden its global footprint.

Henlius Speeds Up Efforts On Ophthalmic Bevacizumab

Shanghai Henlius Biotech has revealed the latest update on its proposed ophthalmic version of biosimilar bevacizumab, with a global Phase III trial beginning as the firm also pursues international filings with partner Essex Bio-Technology.

Henlius Doses First Patient In China For Ophthalmic Bevacizumab

Chinese firms Shanghai Henlius Biotech and Essex Bio-Technology have announced a key milestone in their Chinese Phase I clinical study for the HLX04-O biosimilar bevacizumab candidate to treat wet age-related macular degeneration.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150370

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel